SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

X4 Pharmaceuticals, Inc – ‘10-Q’ for 3/31/20 – ‘EX-10.1’

On:  Thursday, 5/7/20, at 4:54pm ET   ·   For:  3/31/20   ·   Accession #:  1628280-20-6998   ·   File #:  1-38295

Previous ‘10-Q’:  ‘10-Q’ on 11/7/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/4/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 5/7/24 for 3/31/24   ·   9 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/07/20  X4 Pharmaceuticals, Inc           10-Q        3/31/20   73:7.2M                                   Workiva Inc Wde… FA01/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    980K 
 2: EX-10.1     Material Contract                                   HTML     32K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
20: R1          Cover Page                                          HTML     80K 
43: R2          Condensed Consolidated Balance Sheets               HTML     98K 
69: R3          Condensed Consolidated Balance Sheets               HTML     32K 
                (Parenthetical)                                                  
30: R4          Condensed Consolidated Statements of Operations     HTML     86K 
                and Comprehensive Loss                                           
21: R5          Condensed Consolidated Statements of Convertible    HTML     91K 
                Preferred Stock, Redeemable Common Stock and                     
                Stockholders' Equity (Deficit)                                   
45: R6          Condensed Consolidated Statements of Cash Flows     HTML    104K 
71: R7          Nature of the Business and Basis of Presentation    HTML     37K 
28: R8          Summary of Significant Accounting Policies          HTML     79K 
23: R9          License, Collaboration, and Funding Agreements      HTML     35K 
33: R10         Fair Value of Financial Assets and Liabilities      HTML     57K 
12: R11         Property and Equipment, Net                         HTML     41K 
51: R12         Accrued Expenses                                    HTML     36K 
61: R13         Long-Term Debt                                      HTML     56K 
32: R14         Leases                                              HTML     64K 
11: R15         Commitment and Contingencies                        HTML     31K 
50: R16         Preferred and Common Stock Warrants                 HTML    107K 
60: R17         Common Stock                                        HTML     27K 
31: R18         Stock-Based Compensation                            HTML     80K 
13: R19         Income Taxes                                        HTML     25K 
42: R20         Net Loss per Share                                  HTML     52K 
73: R21         Summary of Significant Accounting Policies          HTML     61K 
                (Policies)                                                       
29: R22         Summary of Significant Accounting Policies          HTML     57K 
                (Tables)                                                         
24: R23         Fair Value of Financial Assets and Liabilities      HTML     54K 
                (Tables)                                                         
41: R24         Property and Equipment, Net (Tables)                HTML     41K 
72: R25         Accrued Expenses (Tables)                           HTML     37K 
27: R26         Long-Term Debt (Tables)                             HTML     44K 
22: R27         Leases (Tables)                                     HTML     55K 
44: R28         Preferred and Common Stock Warrants (Tables)        HTML    104K 
70: R29         Stock-Based Compensation (Tables)                   HTML     72K 
55: R30         Net Loss per Share (Tables)                         HTML     53K 
48: R31         Nature of the Business and Basis of Presentation -  HTML     35K 
                Additional Information (Detail)                                  
14: R32         Summary of Significant Accounting Policies -        HTML     40K 
                Schedule of Compensating Balance Arrangements                    
                (Detail)                                                         
34: R33         Summary of Significant Accounting Policies -        HTML     34K 
                Schedule of Reconciliation of Cash, Cash                         
                Equivalents, and Restricted Cash (Detail)                        
57: R34         Summary of Significant Accounting Policies -        HTML     26K 
                Narrative (Details)                                              
49: R35         License, Collaboration, and Funding Agreements -    HTML     44K 
                Additional Information (Detail)                                  
15: R36         Fair Value of Financial Assets and Liabilities -    HTML     46K 
                Schedule of Assets and Liabilities Measured at                   
                Fair Value (Detail)                                              
35: R37         Property and Equipment, Net - Schedule of Property  HTML     44K 
                and Equipment, Net (Detail)                                      
58: R38         Property and Equipment, Net - Additional            HTML     25K 
                Information (Detail)                                             
47: R39         Accrued Expenses - Schedule of Accrued Expenses     HTML     38K 
                (Detail)                                                         
65: R40         Long-Term Debt - Summary of Long Term Debt          HTML     34K 
                (Detail)                                                         
39: R41         Long Term Debt - Hercules Loan Agreement -          HTML    113K 
                Additional Information (Detail)                                  
18: R42         Long-Term Debt - Schedule of Future Principal       HTML     38K 
                Payments and the Final Payments Due (Detail)                     
25: R43         Leases - Additional Information (Detail)            HTML     52K 
66: R44         Leases - Schedule of Components of Lease Expense    HTML     43K 
                (Detail)                                                         
40: R45         Leases - Schedule of Maturities of Lease            HTML     40K 
                Liabilities (Detail)                                             
19: R46         Commitment and Contingencies - Additional           HTML     33K 
                Information (Detail)                                             
26: R47         Preferred and Common Stock Warrants - Additional    HTML     52K 
                Information (Detail)                                             
68: R48         Preferred and Common Stock Warrants - Schedule of   HTML     48K 
                Outstanding Warrants (Detail)                                    
38: R49         Preferred and Common Stock Warrants - Summary of    HTML     74K 
                Outstanding Warrants to Purchase Shares of Common                
                Stock (Detail)                                                   
53: R50         Common Stock, Redeemable Common Stock, and          HTML     34K 
                Convertible Preferred Stock (converted to Common                 
                Stock) - Additional Information (Detail)                         
64: R51         Stock-Based Compensation - Additional Information   HTML     81K 
                (Detail)                                                         
37: R52         Stock-Based Compensation - Schedule of Assumptions  HTML     34K 
                Used in Black-Scholes Option-Pricing Model to                    
                Determine Grant-date Fair Value of Stock Options                 
                Granted (Detail)                                                 
17: R53         Stock-Based Compensation - Summary of Stock Option  HTML     75K 
                Activity (Detail)                                                
52: R54         Stock-Based Compensation - Summary of Stock-Based   HTML     31K 
                Compensation Expense Classification (Detail)                     
63: R55         Income Taxes - Additional Information (Detail)      HTML     32K 
36: R56         Net Loss per Share - Summary of Basic and Diluted   HTML     39K 
                Net loss per Share Attributable to Common                        
                Stockholders (Detail)                                            
16: R57         Net Loss per Share - Additional Information         HTML     36K 
                (Detail)                                                         
54: R58         Net Loss per Share - Schedule of Anti-dilutive      HTML     34K 
                Securities Excluded from Computation of Diluted                  
                Net Loss per Share Attributable to Common                        
                Stockholders (Detail)                                            
67: XML         IDEA XML File -- Filing Summary                      XML    132K 
59: XML         XBRL Instance -- xfor-20200331_htm                   XML   1.46M 
56: EXCEL       IDEA Workbook of Financial Reports                  XLSX     73K 
 7: EX-101.CAL  XBRL Calculations -- xfor-20200331_cal               XML    188K 
 8: EX-101.DEF  XBRL Definitions -- xfor-20200331_def                XML    433K 
 9: EX-101.LAB  XBRL Labels -- xfor-20200331_lab                     XML   1.47M 
10: EX-101.PRE  XBRL Presentations -- xfor-20200331_pre              XML    784K 
 6: EX-101.SCH  XBRL Schema -- xfor-20200331                         XSD    179K 
62: JSON        XBRL Instance as JSON Data -- MetaLinks              292±   455K 
46: ZIP         XBRL Zipped Folder -- 0001628280-20-006998-xbrl      Zip    351K 


‘EX-10.1’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  



Exhibit 10.1
SECOND AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT

This second amendment (this “Amendment”) to that certain Amended and Restated Executive Employment Agreement, dated March 13, 2019, as amended by that certain Amendment to Amended and Restated Executive Employment Agreement, dated February 13, 2020 (the “February 2020 Amendment”) (collectively, the “Agreement”) by and between Paula Ragan, Ph.D (“Employee”) and X4 Pharmaceuticals, Inc. (the “Company”) is entered into as of this 15th day of April, 2020.

WHEREAS, an error was included in the February 2020 Amendment and Employee and the Company desire to correct such error.

In consideration and in furtherance of Employee’s continued at-will employment with the Company, Employee and the Company agree as follows:
1.The below existing language in Section 4(b)(i) and (4(b)(ii) of the Agreement shall be entirely replaced by the replacement language beneath it:

Existing language: “(i) Company shall pay Executive an amount equal to continuation of Executive’s monthly Base Salary for a six (6) month period, with such payments to be made in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions; provided, however, that if Executive’s resignation or termination under this Section occurs within twelve (12) months after a Change of Control (as defined below), then the Company shall instead pay Executive an amount equal to continuation of Executive’s monthly Base Salary for an eighteen (18) month period, with such payments to be made in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions.

(ii) Company shall pay Executive a pro-rata portion of Executive’s at-target Annual Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination, with such payment to be made in on one lump sum in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions; provided, however, that if Executive’s resignation or termination under this Section occurs within twelve (12) months after a Change of Control (as defined below), then the Company shall instead pay Executive an amount equal to Executive’s full Annual Bonus for the calendar year in which the termination occurs in advance of such Annual Bonus being earned, with such payment to be made in on one lump sum in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions.

Replacement language: “(i) Company shall pay Executive an amount equal to continuation of Executive’s monthly Base Salary for a twelve (12) month period, with such payments to be made in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions; provided, however, that if Executive’s resignation or termination under this Section occurs within twelve (12) months after a Change of Control (as defined below), then the Company shall instead pay Executive an amount equal to continuation of Executive’s monthly Base Salary for an eighteen (18) month period, with such payments to be made in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions.

(ii) Company shall pay Executive a pro-rata portion of Executive’s at-target Annual Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination, with such payment to be made in on one lump sum in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions; provided, however, that if Executive’s resignation or termination under this Section occurs within twelve (12) months after a Change of Control (as defined below), then the Company shall instead pay Executive an amount equal to Executive’s full Annual Bonus for the calendar year in which the termination occurs in advance of such Annual Bonus being earned, with such payment to be made in on one lump sum in accordance with Company’s normal payroll practices and schedules, less all customary and required taxes and employment-related deductions.

This Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement between the parties. Except as amended hereby, all of the terms and conditions of the Agreement shall remain and continue in full force and effect.





Exhibit 10.1
IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.

X4 Pharmaceuticals, Inc.Paula Raga, Ph.D, an individual
/s/ Paula Ragan
Name: Michael Wyzga Paula Ragan, Ph.D
Title: Chairman of the Board


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/7/208-K
For Period end:3/31/20
2/13/208-K,  SC 13G/A
3/13/193,  4,  4/A,  8-K
 List all Filings 


9 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  X4 Pharmaceuticals, Inc.          10-K       12/31/23   93:9.5M                                   Workiva Inc Wde… FA01/FA
 3/21/23  X4 Pharmaceuticals, Inc.          10-K       12/31/22   96:34M                                    Workiva Inc Wde… FA01/FA
12/09/22  X4 Pharmaceuticals, Inc.          424B5      12/08/22    1:643K                                   Donnelley … Solutions/FA
12/07/22  X4 Pharmaceuticals, Inc.          424B5                  1:645K                                   Donnelley … Solutions/FA
 3/17/22  X4 Pharmaceuticals, Inc.          10-K       12/31/21  100:10M                                    Workiva Inc Wde… FA01/FA
 1/14/22  X4 Pharmaceuticals, Inc.          424B5                  1:569K                                   Donnelley … Solutions/FA
10/19/20  X4 Pharmaceuticals, Inc.          S-3                    7:1M                                     Donnelley … Solutions/FA
10/16/20  X4 Pharmaceuticals, Inc.          424B5                  1:539K                                   Donnelley … Solutions/FA
 8/07/20  X4 Pharmaceuticals, Inc.          S-3                    8:1.3M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001628280-20-006998   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 8:14:07.2am ET